Q1 2023 Non-GAAP Operating Income
Our 2022 ESG Progress Report Highlights
nnn Progress toward ambitious targets
ā24%
reduction in total scope 1 and 2
greenhouse gas emissions (vs.
2019, ahead of schedule to meet
2025 target: 25%)*
5
access to medicines programs
(2025 target: 8)
21
new regulatory submissions
in low- and middle-income
countries (2025 target: 75)*
-100%
of active employees trained
on compliance policies
(achieved 2022 target: 99%+)
h) Economic impact
$44 billion
in savings from Teva's
generic medicines
across 21 countries
$20 billion
contributed
to GDP
across 24 countries
|16|
Driving Long-Term Sustainability
and Value Creation
* Tied to Teva's sustainable financial instruments (e.g., sustainability-linked bonds and sustainability linked revolving credit facility)
tevaView entire presentation